Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Health Group Inc.

中國醫療集團有限公司

(Carrying on business in Hong Kong as "萬全醫療集團")

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

Voluntary Announcement - Supplementary Information Regarding the 2025 Annual Results and Future Development Strategy

Reference is made to the Company's annual results announcement for the year ended 31 December 2025 (the "Annual Results Announcement"), published on 30 March 2026. This announcement is made on a voluntary basis and is intended to provide supplementary information regarding the Group's business operations and future development.

I. Core business operations continue to perform well, with strong growth momentum

In the 2025 financial year, the Group focused on its core business of post-marketing research and academic promotion services, with revenue increasing by 7.98% year-on-year and gross profit rising by 62.84% year-on-year. The profitability of the Company's core business continues to strengthen, laying a solid foundation for the Company's future development.

II. Provisions for historical accounts receivable have been fully made and do not affect current operations

The net loss reflected in the Group's 2025 financial results primarily stems from the provision for expected credit losses on historical accounts receivable, made in accordance with the principle of prudence. These amounts primarily originate from past business operations. This accounting treatment constitutes a non-cash financial adjustment and will not have any material impact on the Group's current and future core business operations, cash flow position or development strategy.

III. Strategic Deployment Across Three Major AI-RWS Sectors

The Group has made in-depth strategic deployments across three trillion-yuan-scale core AI-RWS sectors, establishing three specialised research centres:

1. Brain Science and Research-Driven Economy Sector (RWS Xien Research Centre)

Focusing on high-prevalence conditions within the silver economy, such as Alzheimer's disease (AD) and stroke, the Group has launched the "Healthy Longevity 150Y Plan". It has secured the rights to conduct real-world clinical studies in the Chinese market over the next decade for products in the anti-dementia field, including Xien Card Micro-tablets™, Xien Mei Orally Disintegrating Flash Tablets™ and Xien Li Oral Solution.

2. Mental Health and Emotional Wellbeing Track (RWS Xixin Research Centre)

Has launched an AI-RWS cohort study covering 15 cities nationwide and over 10,000 patients, securing the rights to conduct real-world clinical research in the Chinese market for the "Five Golden Flowers" series of products, including Xixin Ai, Xixin Qiu You, Xixin Le and Xixin Miao.

3. Allergy Sector (RWS Baiming Research Centre)

Plans are in place to establish a collaborative network involving over 35 Grade A tertiary hospitals across more than 15 provinces and municipalities. The target is to keep the data missing rate below 5% and achieve a compliance rate of over 90% for comorbidity quality control indicators. To provide precise

diagnostic and treatment solutions for patients with allergic comorbidities, including Baimixia, Baimiha, Baimile and Baimiai. Strategically positioning itself across three trillion-yuan AI-RWS core sectors, the Group is establishing three specialised research centres:

IV. Future Outlook

The Group will seize the strategic opportunities presented by the national "14th Five-Year Plan" for the development of the silver economy, continuously deepening its布局 across the three AI-RWS sectors. Leveraging the professional strengths of the three major research centres—Xien, Xixin and Baiming, to focus on key areas such as elderly health, chronic disease management and rehabilitation support. We will continue to generate high-quality real-world evidence, accelerate the R&D and commercialisation of innovative medicines, and contribute to the development of an integrated industrial ecosystem encompassing "medical care, elderly care, rehabilitation and nursing", thereby creating long-term value for shareholders.

Shareholders and potential investors are advised to exercise caution when trading in the Company's securities.

By Order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 1 April 2026

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia, Mr. Raymond Guo; two non-executive Directors, being Dr. ZHANG Li and Dr. WANG Dajun Denis; and four independent non-executive Directors, being Dr. NI Binhui, Mr. WU Shuangsi, Dr. GUO Tong and Ms. LIU Na .

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at *www.hkexnews.hk* for 7 days from the date of its posting. This announcement will also be posted on the Company's website at http://www.chgi.net.